API | efaproxiral

efaproxiral Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Chemistry

SMILES: Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(=O)O)cc2)c1
InChIKey: BNFRJXLZYUTIII-UHFFFAOYSA-N
Mol. Mass: 341.41
ALogP: 3.73 Partition coefficient
ChEMBL Molecules:

efaproxiral

efaproxiral sodium

More Chemistry

Pharmacology

Mechanism of Action:
- Hemoglobin subunit alpha (Homo sapiens) ^UniProt
- Hemoglobin subunit beta (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

2-(4-(2-((3,5-dimethylphenyl)amino)-2-oxoethyl)phenoxy)-2-methylpropanoic acid | 2-(4-(((3,5-dimethylanilino)carbonyl)methyl)phenoxy)-2-methylpropionic acid | 2-dacmpp | efaproxiral | efaproxiral sodium | rsr13 | rsr 13 | rsr-13 | rsr13 cpd | rsr 56 | rsr-56

Organizations (7)

Research & Development (7)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)

Brain Injuries, Traumatic ()

Brain Neoplasms (Phase 1/Phase 2)

Breast Neoplasms (Phase 3)

Depression ()

Lung Neoplasms (Phase 3)

Myocardial Infarction ()

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 3)

Stroke ()

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial Organizations: 7

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue